Compare WYY & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYY | IBIO |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.9M | 52.8M |
| IPO Year | 2005 | 2009 |
| Metric | WYY | IBIO |
|---|---|---|
| Price | $5.91 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.69 |
| AVG Volume (30 Days) | 122.0K | ★ 470.8K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,545,364.00 | N/A |
| Revenue This Year | $12.26 | N/A |
| Revenue Next Year | $25.66 | N/A |
| P/E Ratio | $617.00 | ★ N/A |
| Revenue Growth | ★ 5.59 | N/A |
| 52 Week Low | $3.96 | $0.69 |
| 52 Week High | $24.30 | $3.82 |
| Indicator | WYY | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 37.52 |
| Support Level | $5.60 | $0.71 |
| Resistance Level | $7.74 | $0.85 |
| Average True Range (ATR) | 0.42 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 8.33 | 15.62 |
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.